Review




Structured Review

Broad Institute Inc gsea msigdb ontology gene sets
Gsea Msigdb Ontology Gene Sets, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/msigdb/pmc12170844-182-14-28?v=Broad+Institute+Inc
Average 90 stars, based on 1 article reviews
gsea msigdb ontology gene sets - by Bioz Stars, 2026-07
90/100 stars

Images



Similar Products

86
Human Protein Atlas org gsea msigdb human genesets jsp
Org Gsea Msigdb Human Genesets Jsp, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/msigdb/pm42310464-796-9-10?v=Human+Protein+Atlas
Average 86 stars, based on 1 article reviews
org gsea msigdb human genesets jsp - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Biokey American Instrument Inc msigdb hallmark gene sets in biokey 9 b9 cancer single cells
Decoding drug response in patient samples using single-cell identity annotation (A) UMAP plots show cluster identifications, cell types, and treatment conditions for all single cells in <t>the</t> <t>BIOKEY_9</t> (B9) tumor. These plots provide an overview of the cellular landscape within the tumor, highlighting distinct clusters and their associations with treatment conditions. (B) Single-cell identity changes in the cancer cells of TNBC patient BIOKEY_9 (B9) after pembrolizumab treatment. Pie charts illustrate the distribution of single cells across different identities within the cancer cell population before and after treatment. (C) Identity scores for single cells in the BIOKEY_9 (B9) cancer cell population before and after pembrolizumab treatment. These scores quantify the intensity of gene expression identities at the single-cell level, revealing shifts in cellular identities induced by treatment. Boxplot center line indicates median; box bounds represent the interquartile range (IQR); whiskers extend to 1.5×IQR. (D) GSEA results for F1 and F2 gene sets after pembrolizumab treatment, highlighting the enrichment or depletion of these identity-specific gene sets in the treated cancer cell population. (E) Expression scores for three MsigDB hallmark gene sets in BIOKEY_9 (B9) cancer single cells before and after treatment. The hallmark gene sets analyzed include estrogen response (early and late combined), TNFα signaling via NF-κB, and epithelial-mesenchymal transition (EMT), providing insights into treatment-induced changes in key biological pathways. Violin plots show the distribution of expression scores. (F) Volcano plots of differentially expressed genes (DEGs) in BIOKEY_9 (B9) cancer single cells after pembrolizumab treatment. Pie charts accompanying the plots display the percentage of DEGs associated with each identity in the CCLE model. The right pie chart represents upregulated genes, while the left represents downregulated genes, linking these changes to specific identities. (G) Analysis of identity composition changes in three cancer cell clusters from BIOKEY_9, B9 (cluster_0, cluster_6, and cluster_3), before and after pembrolizumab treatment. Pie charts illustrate the percentage of single cells belonging to each identity within each cluster, revealing differential responses across clusters. (H) Global characterization of identity enrichment or depletion for cancer cells within 11 TNBC tumors following anti-PD1 treatment. Chi-squared test results assess the significance of identity changes across tumors, with stacked bar plots depicting residual scores for each identity. Positive residual scores indicate identity expansion, while negative scores indicate depletion. (I) Analysis of cancer cell clusters contributing to the largest identity expansions in cancer cells for each tumor. Chi-squared test p -values assess whether specific clusters are more associated with identity expansion compared to other clusters within the same tumor. Stacked bar plots represent the residual scores for each cluster, highlighting their contributions to identity changes. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by the Wilcoxon rank-sum test (C and E) or by chi-squared test (H and I).
Msigdb Hallmark Gene Sets In Biokey 9 B9 Cancer Single Cells, supplied by Biokey American Instrument Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/msigdb/pmc13138057-215-49-54?v=Biokey+American+Instrument+Inc
Average 86 stars, based on 1 article reviews
msigdb hallmark gene sets in biokey 9 b9 cancer single cells - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Partek molecular signatures database msigdb cancer hallmark gene set
Decoding drug response in patient samples using single-cell identity annotation (A) UMAP plots show cluster identifications, cell types, and treatment conditions for all single cells in <t>the</t> <t>BIOKEY_9</t> (B9) tumor. These plots provide an overview of the cellular landscape within the tumor, highlighting distinct clusters and their associations with treatment conditions. (B) Single-cell identity changes in the cancer cells of TNBC patient BIOKEY_9 (B9) after pembrolizumab treatment. Pie charts illustrate the distribution of single cells across different identities within the cancer cell population before and after treatment. (C) Identity scores for single cells in the BIOKEY_9 (B9) cancer cell population before and after pembrolizumab treatment. These scores quantify the intensity of gene expression identities at the single-cell level, revealing shifts in cellular identities induced by treatment. Boxplot center line indicates median; box bounds represent the interquartile range (IQR); whiskers extend to 1.5×IQR. (D) GSEA results for F1 and F2 gene sets after pembrolizumab treatment, highlighting the enrichment or depletion of these identity-specific gene sets in the treated cancer cell population. (E) Expression scores for three MsigDB hallmark gene sets in BIOKEY_9 (B9) cancer single cells before and after treatment. The hallmark gene sets analyzed include estrogen response (early and late combined), TNFα signaling via NF-κB, and epithelial-mesenchymal transition (EMT), providing insights into treatment-induced changes in key biological pathways. Violin plots show the distribution of expression scores. (F) Volcano plots of differentially expressed genes (DEGs) in BIOKEY_9 (B9) cancer single cells after pembrolizumab treatment. Pie charts accompanying the plots display the percentage of DEGs associated with each identity in the CCLE model. The right pie chart represents upregulated genes, while the left represents downregulated genes, linking these changes to specific identities. (G) Analysis of identity composition changes in three cancer cell clusters from BIOKEY_9, B9 (cluster_0, cluster_6, and cluster_3), before and after pembrolizumab treatment. Pie charts illustrate the percentage of single cells belonging to each identity within each cluster, revealing differential responses across clusters. (H) Global characterization of identity enrichment or depletion for cancer cells within 11 TNBC tumors following anti-PD1 treatment. Chi-squared test results assess the significance of identity changes across tumors, with stacked bar plots depicting residual scores for each identity. Positive residual scores indicate identity expansion, while negative scores indicate depletion. (I) Analysis of cancer cell clusters contributing to the largest identity expansions in cancer cells for each tumor. Chi-squared test p -values assess whether specific clusters are more associated with identity expansion compared to other clusters within the same tumor. Stacked bar plots represent the residual scores for each cluster, highlighting their contributions to identity changes. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by the Wilcoxon rank-sum test (C and E) or by chi-squared test (H and I).
Molecular Signatures Database Msigdb Cancer Hallmark Gene Set, supplied by Partek, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/msigdb/pmc13013501-97-10-7?v=Partek
Average 86 stars, based on 1 article reviews
molecular signatures database msigdb cancer hallmark gene set - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Bioplanet msigdb hallmark 2020
Decoding drug response in patient samples using single-cell identity annotation (A) UMAP plots show cluster identifications, cell types, and treatment conditions for all single cells in <t>the</t> <t>BIOKEY_9</t> (B9) tumor. These plots provide an overview of the cellular landscape within the tumor, highlighting distinct clusters and their associations with treatment conditions. (B) Single-cell identity changes in the cancer cells of TNBC patient BIOKEY_9 (B9) after pembrolizumab treatment. Pie charts illustrate the distribution of single cells across different identities within the cancer cell population before and after treatment. (C) Identity scores for single cells in the BIOKEY_9 (B9) cancer cell population before and after pembrolizumab treatment. These scores quantify the intensity of gene expression identities at the single-cell level, revealing shifts in cellular identities induced by treatment. Boxplot center line indicates median; box bounds represent the interquartile range (IQR); whiskers extend to 1.5×IQR. (D) GSEA results for F1 and F2 gene sets after pembrolizumab treatment, highlighting the enrichment or depletion of these identity-specific gene sets in the treated cancer cell population. (E) Expression scores for three MsigDB hallmark gene sets in BIOKEY_9 (B9) cancer single cells before and after treatment. The hallmark gene sets analyzed include estrogen response (early and late combined), TNFα signaling via NF-κB, and epithelial-mesenchymal transition (EMT), providing insights into treatment-induced changes in key biological pathways. Violin plots show the distribution of expression scores. (F) Volcano plots of differentially expressed genes (DEGs) in BIOKEY_9 (B9) cancer single cells after pembrolizumab treatment. Pie charts accompanying the plots display the percentage of DEGs associated with each identity in the CCLE model. The right pie chart represents upregulated genes, while the left represents downregulated genes, linking these changes to specific identities. (G) Analysis of identity composition changes in three cancer cell clusters from BIOKEY_9, B9 (cluster_0, cluster_6, and cluster_3), before and after pembrolizumab treatment. Pie charts illustrate the percentage of single cells belonging to each identity within each cluster, revealing differential responses across clusters. (H) Global characterization of identity enrichment or depletion for cancer cells within 11 TNBC tumors following anti-PD1 treatment. Chi-squared test results assess the significance of identity changes across tumors, with stacked bar plots depicting residual scores for each identity. Positive residual scores indicate identity expansion, while negative scores indicate depletion. (I) Analysis of cancer cell clusters contributing to the largest identity expansions in cancer cells for each tumor. Chi-squared test p -values assess whether specific clusters are more associated with identity expansion compared to other clusters within the same tumor. Stacked bar plots represent the residual scores for each cluster, highlighting their contributions to identity changes. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by the Wilcoxon rank-sum test (C and E) or by chi-squared test (H and I).
Msigdb Hallmark 2020, supplied by Bioplanet, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/msigdb/pmc12468448-54-11-9?v=Bioplanet
Average 86 stars, based on 1 article reviews
msigdb hallmark 2020 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

90
Broad Institute Inc gsea msigdb ontology gene sets
Decoding drug response in patient samples using single-cell identity annotation (A) UMAP plots show cluster identifications, cell types, and treatment conditions for all single cells in <t>the</t> <t>BIOKEY_9</t> (B9) tumor. These plots provide an overview of the cellular landscape within the tumor, highlighting distinct clusters and their associations with treatment conditions. (B) Single-cell identity changes in the cancer cells of TNBC patient BIOKEY_9 (B9) after pembrolizumab treatment. Pie charts illustrate the distribution of single cells across different identities within the cancer cell population before and after treatment. (C) Identity scores for single cells in the BIOKEY_9 (B9) cancer cell population before and after pembrolizumab treatment. These scores quantify the intensity of gene expression identities at the single-cell level, revealing shifts in cellular identities induced by treatment. Boxplot center line indicates median; box bounds represent the interquartile range (IQR); whiskers extend to 1.5×IQR. (D) GSEA results for F1 and F2 gene sets after pembrolizumab treatment, highlighting the enrichment or depletion of these identity-specific gene sets in the treated cancer cell population. (E) Expression scores for three MsigDB hallmark gene sets in BIOKEY_9 (B9) cancer single cells before and after treatment. The hallmark gene sets analyzed include estrogen response (early and late combined), TNFα signaling via NF-κB, and epithelial-mesenchymal transition (EMT), providing insights into treatment-induced changes in key biological pathways. Violin plots show the distribution of expression scores. (F) Volcano plots of differentially expressed genes (DEGs) in BIOKEY_9 (B9) cancer single cells after pembrolizumab treatment. Pie charts accompanying the plots display the percentage of DEGs associated with each identity in the CCLE model. The right pie chart represents upregulated genes, while the left represents downregulated genes, linking these changes to specific identities. (G) Analysis of identity composition changes in three cancer cell clusters from BIOKEY_9, B9 (cluster_0, cluster_6, and cluster_3), before and after pembrolizumab treatment. Pie charts illustrate the percentage of single cells belonging to each identity within each cluster, revealing differential responses across clusters. (H) Global characterization of identity enrichment or depletion for cancer cells within 11 TNBC tumors following anti-PD1 treatment. Chi-squared test results assess the significance of identity changes across tumors, with stacked bar plots depicting residual scores for each identity. Positive residual scores indicate identity expansion, while negative scores indicate depletion. (I) Analysis of cancer cell clusters contributing to the largest identity expansions in cancer cells for each tumor. Chi-squared test p -values assess whether specific clusters are more associated with identity expansion compared to other clusters within the same tumor. Stacked bar plots represent the residual scores for each cluster, highlighting their contributions to identity changes. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by the Wilcoxon rank-sum test (C and E) or by chi-squared test (H and I).
Gsea Msigdb Ontology Gene Sets, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/msigdb/pmc12170844-182-14-28?v=Broad+Institute+Inc
Average 90 stars, based on 1 article reviews
gsea msigdb ontology gene sets - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Broad Institute Inc msigdb
Decoding drug response in patient samples using single-cell identity annotation (A) UMAP plots show cluster identifications, cell types, and treatment conditions for all single cells in <t>the</t> <t>BIOKEY_9</t> (B9) tumor. These plots provide an overview of the cellular landscape within the tumor, highlighting distinct clusters and their associations with treatment conditions. (B) Single-cell identity changes in the cancer cells of TNBC patient BIOKEY_9 (B9) after pembrolizumab treatment. Pie charts illustrate the distribution of single cells across different identities within the cancer cell population before and after treatment. (C) Identity scores for single cells in the BIOKEY_9 (B9) cancer cell population before and after pembrolizumab treatment. These scores quantify the intensity of gene expression identities at the single-cell level, revealing shifts in cellular identities induced by treatment. Boxplot center line indicates median; box bounds represent the interquartile range (IQR); whiskers extend to 1.5×IQR. (D) GSEA results for F1 and F2 gene sets after pembrolizumab treatment, highlighting the enrichment or depletion of these identity-specific gene sets in the treated cancer cell population. (E) Expression scores for three MsigDB hallmark gene sets in BIOKEY_9 (B9) cancer single cells before and after treatment. The hallmark gene sets analyzed include estrogen response (early and late combined), TNFα signaling via NF-κB, and epithelial-mesenchymal transition (EMT), providing insights into treatment-induced changes in key biological pathways. Violin plots show the distribution of expression scores. (F) Volcano plots of differentially expressed genes (DEGs) in BIOKEY_9 (B9) cancer single cells after pembrolizumab treatment. Pie charts accompanying the plots display the percentage of DEGs associated with each identity in the CCLE model. The right pie chart represents upregulated genes, while the left represents downregulated genes, linking these changes to specific identities. (G) Analysis of identity composition changes in three cancer cell clusters from BIOKEY_9, B9 (cluster_0, cluster_6, and cluster_3), before and after pembrolizumab treatment. Pie charts illustrate the percentage of single cells belonging to each identity within each cluster, revealing differential responses across clusters. (H) Global characterization of identity enrichment or depletion for cancer cells within 11 TNBC tumors following anti-PD1 treatment. Chi-squared test results assess the significance of identity changes across tumors, with stacked bar plots depicting residual scores for each identity. Positive residual scores indicate identity expansion, while negative scores indicate depletion. (I) Analysis of cancer cell clusters contributing to the largest identity expansions in cancer cells for each tumor. Chi-squared test p -values assess whether specific clusters are more associated with identity expansion compared to other clusters within the same tumor. Stacked bar plots represent the residual scores for each cluster, highlighting their contributions to identity changes. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by the Wilcoxon rank-sum test (C and E) or by chi-squared test (H and I).
Msigdb, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/msigdb/pm40489463-108-38-25?v=Broad+Institute+Inc
Average 90 stars, based on 1 article reviews
msigdb - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Broad Institute Inc msigdb resource
Decoding drug response in patient samples using single-cell identity annotation (A) UMAP plots show cluster identifications, cell types, and treatment conditions for all single cells in <t>the</t> <t>BIOKEY_9</t> (B9) tumor. These plots provide an overview of the cellular landscape within the tumor, highlighting distinct clusters and their associations with treatment conditions. (B) Single-cell identity changes in the cancer cells of TNBC patient BIOKEY_9 (B9) after pembrolizumab treatment. Pie charts illustrate the distribution of single cells across different identities within the cancer cell population before and after treatment. (C) Identity scores for single cells in the BIOKEY_9 (B9) cancer cell population before and after pembrolizumab treatment. These scores quantify the intensity of gene expression identities at the single-cell level, revealing shifts in cellular identities induced by treatment. Boxplot center line indicates median; box bounds represent the interquartile range (IQR); whiskers extend to 1.5×IQR. (D) GSEA results for F1 and F2 gene sets after pembrolizumab treatment, highlighting the enrichment or depletion of these identity-specific gene sets in the treated cancer cell population. (E) Expression scores for three MsigDB hallmark gene sets in BIOKEY_9 (B9) cancer single cells before and after treatment. The hallmark gene sets analyzed include estrogen response (early and late combined), TNFα signaling via NF-κB, and epithelial-mesenchymal transition (EMT), providing insights into treatment-induced changes in key biological pathways. Violin plots show the distribution of expression scores. (F) Volcano plots of differentially expressed genes (DEGs) in BIOKEY_9 (B9) cancer single cells after pembrolizumab treatment. Pie charts accompanying the plots display the percentage of DEGs associated with each identity in the CCLE model. The right pie chart represents upregulated genes, while the left represents downregulated genes, linking these changes to specific identities. (G) Analysis of identity composition changes in three cancer cell clusters from BIOKEY_9, B9 (cluster_0, cluster_6, and cluster_3), before and after pembrolizumab treatment. Pie charts illustrate the percentage of single cells belonging to each identity within each cluster, revealing differential responses across clusters. (H) Global characterization of identity enrichment or depletion for cancer cells within 11 TNBC tumors following anti-PD1 treatment. Chi-squared test results assess the significance of identity changes across tumors, with stacked bar plots depicting residual scores for each identity. Positive residual scores indicate identity expansion, while negative scores indicate depletion. (I) Analysis of cancer cell clusters contributing to the largest identity expansions in cancer cells for each tumor. Chi-squared test p -values assess whether specific clusters are more associated with identity expansion compared to other clusters within the same tumor. Stacked bar plots represent the residual scores for each cluster, highlighting their contributions to identity changes. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by the Wilcoxon rank-sum test (C and E) or by chi-squared test (H and I).
Msigdb Resource, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/msigdb/pmc12129451-410-29-34?v=Broad+Institute+Inc
Average 90 stars, based on 1 article reviews
msigdb resource - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Broad Institute Inc msigdb database
Results of <t>the</t> <t>GSEA</t> analysis for transcriptomic profiles of GATA3–METH versus GATA3–CTRL, and GATA3–LOFDEL versus GATA3–CTRL tumours in the TCGA–BRCA dataset. GSEA plots illustrate the main enrichment or depletion profiles. For all the gene sets, the enrichment or depletion was considered significant with a nominal P -value < 0.05 and FDR < 0.25. The gene sets were selected from the Broad Institute’s <t>MSigDB</t> database of the (MSigDB collections C2, C5, or H). Significance levels are indicated using asterisks. For P -values, the following significance symbols were used: * for P < 0.05, ** for P < 0.01, and *** for P < 0.001. For FDR-adjusted values: * indicates FDR < 0.25, ** indicates FDR < 0.1, and *** indicates FDR < 0.05.
Msigdb Database, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/msigdb/pmc12203794-153-17-24?v=Broad+Institute+Inc
Average 90 stars, based on 1 article reviews
msigdb database - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Decoding drug response in patient samples using single-cell identity annotation (A) UMAP plots show cluster identifications, cell types, and treatment conditions for all single cells in the BIOKEY_9 (B9) tumor. These plots provide an overview of the cellular landscape within the tumor, highlighting distinct clusters and their associations with treatment conditions. (B) Single-cell identity changes in the cancer cells of TNBC patient BIOKEY_9 (B9) after pembrolizumab treatment. Pie charts illustrate the distribution of single cells across different identities within the cancer cell population before and after treatment. (C) Identity scores for single cells in the BIOKEY_9 (B9) cancer cell population before and after pembrolizumab treatment. These scores quantify the intensity of gene expression identities at the single-cell level, revealing shifts in cellular identities induced by treatment. Boxplot center line indicates median; box bounds represent the interquartile range (IQR); whiskers extend to 1.5×IQR. (D) GSEA results for F1 and F2 gene sets after pembrolizumab treatment, highlighting the enrichment or depletion of these identity-specific gene sets in the treated cancer cell population. (E) Expression scores for three MsigDB hallmark gene sets in BIOKEY_9 (B9) cancer single cells before and after treatment. The hallmark gene sets analyzed include estrogen response (early and late combined), TNFα signaling via NF-κB, and epithelial-mesenchymal transition (EMT), providing insights into treatment-induced changes in key biological pathways. Violin plots show the distribution of expression scores. (F) Volcano plots of differentially expressed genes (DEGs) in BIOKEY_9 (B9) cancer single cells after pembrolizumab treatment. Pie charts accompanying the plots display the percentage of DEGs associated with each identity in the CCLE model. The right pie chart represents upregulated genes, while the left represents downregulated genes, linking these changes to specific identities. (G) Analysis of identity composition changes in three cancer cell clusters from BIOKEY_9, B9 (cluster_0, cluster_6, and cluster_3), before and after pembrolizumab treatment. Pie charts illustrate the percentage of single cells belonging to each identity within each cluster, revealing differential responses across clusters. (H) Global characterization of identity enrichment or depletion for cancer cells within 11 TNBC tumors following anti-PD1 treatment. Chi-squared test results assess the significance of identity changes across tumors, with stacked bar plots depicting residual scores for each identity. Positive residual scores indicate identity expansion, while negative scores indicate depletion. (I) Analysis of cancer cell clusters contributing to the largest identity expansions in cancer cells for each tumor. Chi-squared test p -values assess whether specific clusters are more associated with identity expansion compared to other clusters within the same tumor. Stacked bar plots represent the residual scores for each cluster, highlighting their contributions to identity changes. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by the Wilcoxon rank-sum test (C and E) or by chi-squared test (H and I).

Journal: iScience

Article Title: Decoding drug-responsive cell subpopulations in triple-negative breast cancer using single-cell multiomics

doi: 10.1016/j.isci.2026.115445

Figure Lengend Snippet: Decoding drug response in patient samples using single-cell identity annotation (A) UMAP plots show cluster identifications, cell types, and treatment conditions for all single cells in the BIOKEY_9 (B9) tumor. These plots provide an overview of the cellular landscape within the tumor, highlighting distinct clusters and their associations with treatment conditions. (B) Single-cell identity changes in the cancer cells of TNBC patient BIOKEY_9 (B9) after pembrolizumab treatment. Pie charts illustrate the distribution of single cells across different identities within the cancer cell population before and after treatment. (C) Identity scores for single cells in the BIOKEY_9 (B9) cancer cell population before and after pembrolizumab treatment. These scores quantify the intensity of gene expression identities at the single-cell level, revealing shifts in cellular identities induced by treatment. Boxplot center line indicates median; box bounds represent the interquartile range (IQR); whiskers extend to 1.5×IQR. (D) GSEA results for F1 and F2 gene sets after pembrolizumab treatment, highlighting the enrichment or depletion of these identity-specific gene sets in the treated cancer cell population. (E) Expression scores for three MsigDB hallmark gene sets in BIOKEY_9 (B9) cancer single cells before and after treatment. The hallmark gene sets analyzed include estrogen response (early and late combined), TNFα signaling via NF-κB, and epithelial-mesenchymal transition (EMT), providing insights into treatment-induced changes in key biological pathways. Violin plots show the distribution of expression scores. (F) Volcano plots of differentially expressed genes (DEGs) in BIOKEY_9 (B9) cancer single cells after pembrolizumab treatment. Pie charts accompanying the plots display the percentage of DEGs associated with each identity in the CCLE model. The right pie chart represents upregulated genes, while the left represents downregulated genes, linking these changes to specific identities. (G) Analysis of identity composition changes in three cancer cell clusters from BIOKEY_9, B9 (cluster_0, cluster_6, and cluster_3), before and after pembrolizumab treatment. Pie charts illustrate the percentage of single cells belonging to each identity within each cluster, revealing differential responses across clusters. (H) Global characterization of identity enrichment or depletion for cancer cells within 11 TNBC tumors following anti-PD1 treatment. Chi-squared test results assess the significance of identity changes across tumors, with stacked bar plots depicting residual scores for each identity. Positive residual scores indicate identity expansion, while negative scores indicate depletion. (I) Analysis of cancer cell clusters contributing to the largest identity expansions in cancer cells for each tumor. Chi-squared test p -values assess whether specific clusters are more associated with identity expansion compared to other clusters within the same tumor. Stacked bar plots represent the residual scores for each cluster, highlighting their contributions to identity changes. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by the Wilcoxon rank-sum test (C and E) or by chi-squared test (H and I).

Article Snippet: Boxplot center line indicates median; box bounds represent the interquartile range (IQR); whiskers extend to 1.5×IQR. (D) GSEA results for F1 and F2 gene sets after pembrolizumab treatment, highlighting the enrichment or depletion of these identity-specific gene sets in the treated cancer cell population. (E) Expression scores for three MsigDB hallmark gene sets in BIOKEY_9 (B9) cancer single cells before and after treatment.

Techniques: Single Cell, Gene Expression, Expressing

Results of the GSEA analysis for transcriptomic profiles of GATA3–METH versus GATA3–CTRL, and GATA3–LOFDEL versus GATA3–CTRL tumours in the TCGA–BRCA dataset. GSEA plots illustrate the main enrichment or depletion profiles. For all the gene sets, the enrichment or depletion was considered significant with a nominal P -value < 0.05 and FDR < 0.25. The gene sets were selected from the Broad Institute’s MSigDB database of the (MSigDB collections C2, C5, or H). Significance levels are indicated using asterisks. For P -values, the following significance symbols were used: * for P < 0.05, ** for P < 0.01, and *** for P < 0.001. For FDR-adjusted values: * indicates FDR < 0.25, ** indicates FDR < 0.1, and *** indicates FDR < 0.05.

Journal: NAR Cancer

Article Title: Discovery of epigenetically silenced tumour suppressor genes in aggressive breast cancer through a computational approach

doi: 10.1093/narcan/zcaf020

Figure Lengend Snippet: Results of the GSEA analysis for transcriptomic profiles of GATA3–METH versus GATA3–CTRL, and GATA3–LOFDEL versus GATA3–CTRL tumours in the TCGA–BRCA dataset. GSEA plots illustrate the main enrichment or depletion profiles. For all the gene sets, the enrichment or depletion was considered significant with a nominal P -value < 0.05 and FDR < 0.25. The gene sets were selected from the Broad Institute’s MSigDB database of the (MSigDB collections C2, C5, or H). Significance levels are indicated using asterisks. For P -values, the following significance symbols were used: * for P < 0.05, ** for P < 0.01, and *** for P < 0.001. For FDR-adjusted values: * indicates FDR < 0.25, ** indicates FDR < 0.1, and *** indicates FDR < 0.05.

Article Snippet: More than 10000 published gene sets are publicly available for GSEA analysis in several collections of the MSigDB database [ , ] on the Broad Institute website ( https://www.gsea-msigdb.org/gsea/msigdb ).

Techniques: